Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4006896 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A LY4006896 + Placebo | EXPERIMENTAL | Healthy participants will receive a single escalating dose of LY4006896 and matching placebo. |
| Part B LY4006896 + Placebo | EXPERIMENTAL | Participants with Parkinson's disease will receive multiple doses of LY4006896 and matching placebo. |
| Name | Type | Description |
|---|---|---|
| LY4006896 | DRUG | Administered intravenously (IV) |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: Part A Single Ascending Dose (SAD) and B Multiple Dose (MD) * Have a body mass index within the range of 18 to 34 kilogram per square meter (kg/m²) (inclusive). * For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the pa...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
LY4006896 is an investigational small molecule drug being developed by Eli Lilly and Company for Parkinson disease. It is in Phase 1 clinical development and has not been approved by the FDA. It is being studied in a single trial that includes both healthy participants and participants with Parkinson disease.
LY4006896 is being studied as a potential treatment for Parkinson disease. It is an investigational therapy in Phase 1 testing, so its use remains limited to clinical research at this stage. The ongoing trial enrolls adults with Parkinson disease alongside healthy volunteers.
LY4006896 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the drug in healthy participants and participants with Parkinson disease.
LY4006896 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The Phase 1 program consists of one recruiting trial with a planned enrollment of 90 participants, and no completed trials have been reported for this asset.
LY4006896 is being evaluated in the Phase 1 trial NCT06809400, titled A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease. The trial is currently recruiting, has a planned enrollment of 90 participants, and is being conducted in the United States and Japan.
Yes. The Phase 1 trial NCT06809400 for LY4006896 is randomized and controlled, though it is not double blinded. It is recruiting 90 participants aged 30 years and older, of any sex, and includes healthy volunteers as well as participants with Parkinson disease.